Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers

Exclusion Criteria

• •A participant (vaccinees, household contacts, and intimate contacts) will be excluded if they have the following:
• •1\. Any condition that, in the investigator's judgement, places the subject at undue risk by participating in the study.
• •1. History of any prior disease or therapy which would affect immune or pulmonary function.
• •2. Prior malignancy, except curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
• •3. History of radiation therapy or cytotoxic/cancer chemotherapy.
• •4. History of uncontrolled diabetes mellitus (DM). Type 2 DM controlled with diet alone (and confirmed by HgbA1c \<= 8% within the last 6 months) or a history of isolated gestational diabetes are not exclusionary. Enrollment of individuals with Type 2 DM that is well controlled on hypoglycemic agent(s) may be considered on a case-by-case basis, provided that the HgbA1c is \<= 8% within the last 6 months
• •5. Immunodeficiency or autoimmune disease.
• •6. Acute infection or a recent history (within 6 months) of chronic infection suggestive of immunodeficiency.
• •7. Taking any glucocorticoids or other immunosuppressive medications.
• •8. Asthma is excluded if the participant has ANY of the following:
• •1. Required either oral or parenteral corticosteroids for an exacerbation 2 or more times within the past year, OR
• •2. Needed emergency care, urgent care, hospitalization, or intubation for an acute asthma exacerbation within the past year (eg, would NOT exclude individuals with asthma who meet all other criteria but sought urgent/emergent care solely for asthma medication refills or co-existing conditions unrelated to asthma); OR
• •3. Uses a short-acting rescue inhaler more than 2 days/week for acute asthma symptoms (i.e., not for preventive treatment prior to athletic activity); OR
• •4. Uses medium-to-high-dose inhaled corticosteroids (greater than 250 mcg fluticasone or therapeutic equivalent per day), whether in single-therapy or dual-therapy inhalers (i.e., with a long-acting beta agonist), OR
• •5. Uses more than 1 medication for maintenance therapy daily. Inclusion of anyone on a stable dose of more than 1 medication for maintenance therapy daily for greater than 2 years requires OCRPRO Clinical Safety Office approval.
• •9. Other chronic respiratory disorders including emphysema, interstitial lung disease, pulmonary hypertension, recurrent pneumonia, or recent or ongoing respiratory tract infection. If a respiratory disorder is transient, the study vaccination may be deferred without excluding the participant.
• •10. Female of childbearing potential who is breast-feeding or planning pregnancy during the period from enrollment through 21 days following the last study vaccination.
• •1. Any medical, psychiatric, or social condition, or occupational or other responsibility that, in the judgment of the investigator, would interfere with or serve as a contraindication to receipt of live virus vaccine, protocol adherence, or a participant's ability to give informed consent.
• •2. Psychiatric condition that precludes compliance with the protocol; past or present psychoses; past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years; disorder requiring lithium; or suicidal ideation occurring within five years prior to enrollment.
• •3. Individuals that live in the same house or apartment with any of the following will be excluded:
• •1. An individual under 18 years of age.
• •2. An elderly individual (\>65 years of age).
• •3. An immunocompromised or immunosuppressed individual.
• •4. An individual with chronic respiratory disease.
• •5. A woman who is currently pregnant or breastfeeding or planning a pregnancy during the period of vaccination.
• •4. Individuals who provide hands-on care to immunodeficient, unstable, elderly, or children \<18 years of age within 21 days following each of the first and second vaccination timepoints.
• •5. Receipt of any of the following:
• •* Antiviral medications within 30 days prior to vaccination.
• •* Blood products within 120 days prior to HIV screening.
• •* Immunoglobulin within 60 days prior to HIV screening.
• •* Investigational research drugs or any other investigational agent that in the judgement of the Principal Investigator might interact with the study vaccine within 30 days prior to initial study vaccine administration.
• •* Allergy treatment with antigen injections within 30 days of study vaccine administration.
• •6. Active hepatitis B or C infection (i.e., hepatitis B or C positive serology with the presence of virus antigen or DNA). Ongoing viral replication will be confirmed by a hepatitis B antigen test or hepatitis C viral load.
• •7. History of Guillain-Barre syndrome.
• •8. Indeterminate HIV Western blot test.
• •9. Prior receipt of the Merck Ad5-based HIV vaccine.